Lupin announced that it has received an approval from US Food and Administration (USFDA) for its abbreviated new drug application (ANDA) for Raltegravir Tablets USP, 600 mg.

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

The product, available in 200 mg, 400 mg, 600 mg, and 800 mg strengths, is the generic equivalent of Sumitomo Pharma ...

Research and Development (R&D) Expenses: R&D expenses decreased to $5.8 million for the three months ended March 31, 2025, ...

In a precedential decision issued May 6, 2025, the Federal Circuit reversed in part and vacated in part a Delaware district ...

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, ...

An advocate for cancer patients has said that patients will "die waiting" for cancer treatments in Ireland after a study ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

As part of the 10th Mediterranean Neuroscience Society Conference, we are excited to present this new collection of articles ...

A BC Supreme Court judge has issued an arrest warrant for a man who's accused of running a “campaign of harassment and ...

Toms River Mayor Daniel Rodrick and Ocean County Republican George Gilmore might be in the same political party, but are not ...